
    
      Approximately 25 patients, male or female, age 18 and older, regardless of race or ethnicity,
      will participate in this study at UAMS (University of Arkansas for Medical Sciences) only.

      Participants will receive two courses of chemotherapy with a regimen called DT PACE +
      Rituxan. This regimen consists of 6 drugs: Dexamethasone, Thalidomide, cis-Platinum,
      Adriamycin, Cyclophosphamide, and Etoposide.
    
  